Autopsy report · NCT00118300

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer

“Competing studies”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Case Comprehensive Cancer Center

Sponsor type

University, hospital or other

Conditions

Cervical Cancer; Endometrial Cancer; Ovarian Cancer; Vaginal Cancer

Interventions

capecitabine; brachytherapy; radiation therapy

Participants

0

Sites

2

Countries

United States

Trials that died the same way

• Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
  “Due to Competing Studies” (89% match in meaning)
• Radiation Use During Vemurafenib Treatment
  “Competing Trials” (68% match in meaning)
• Study of Dara-Pembro for Multiple Myeloma Patients
  “Low enrollment due to competing studies” (66% match in meaning)
• Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
  “the study was closed early due to competing trials” (66% match in meaning)
• Use of Magnetic Imaging to Asses the Efficacy of Cap Assisted Colonoscopy in Reducing Looping and Improving Patient Acceptance for the Colonoscopy Procedure
  “The study was incorporated in another study.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.